Enhanced recovery after surgery improves clinical outcomes of liver transplant recipients
-
摘要:
目的 探讨加速康复外科(ERAS)方案在肝移植受者中实施的合理性及有效性。 方法 回顾性分析465例肝移植受者的临床资料。根据有否接受ERAS方案治疗将受者分为ERAS组(163例)和对照组(302例),ERAS组病情重于对照组。观察并记录肝移植受者的手术情况,包括手术时间、无肝期、术中输血量;记录肝移植受者的术后恢复情况,包括术后重症监护室(ICU)住院时间、总住院时间、术后28 d总撤除呼吸机时间、术后再插管率;记录肝移植受者术后90、180 d及1年的生存率,分析肝移植受者生存率的影响因素。 结果 ERAS组受者的无肝期为45(39,53)min, 明显长于对照组的40(32,48)min(P < 0.05)。ERAS组红细胞输注量为10(7,13)U,明显少于对照组的18(10,28)U(P < 0.05)。ERAS组受者的术后ICU住院时间、总住院时间分别为135(84,212)h、24(18,33)d,均短于对照组的154(103,253)h、34(20,50)d(均为P < 0.05)。ERAS组受者的术后28 d总撤除呼吸机时间为26(25,27) d,明显长于对照组的26(23,27) d(P < 0.05)。ERAS组受者的术后再插管率为11.0%,明显低于对照组的20.8%(P < 0.05)。ERAS组受者术后90、180 d以及1年的生存率均为92.8%,均明显高于对照组受者的81.1%、78.1%、75.7%(均为P < 0.05)。ERAS和手术时间是肝移植受者生存率的独立影响因素(P < 0.05)。 结论 肝移植术后ERAS管理模式可提高受者生存率,同时可缩短受者的住院时间、降低再插管率,对肝移植术后康复具有积极的促进作用。 Abstract:Objective To investigate the rationality and efficacy of enhanced recovery after surgery (ERAS) in liver transplant recipients. Methods Clinical data of 465 liver transplant recipients were retrospectively analyzed. All recipients were divided into the ERAS group (n=163) and control group (n=302) according to whether they received ERAS. The severity of disease in the ERAS group was worse than that in the control group. Operation situations including the operation time, anhepatic phase and intraoperative blood transfusion volume of the liver transplant recipients were observed and recorded. Postoperative recovery conditions including the length of intensive care unit (ICU) stay, total length of hospital stay, total ventilator removal time at postoperative 28 d and postoperative re-intubation rate were recorded. The survival rates at 90 d, 180 d and 1 year after liver transplantation were calculated. The influencing factors of survival rate of liver transplant recipients were analyzed. Results The anhepatic phase in the ERAS group was 45 (39, 53) min, significantly longer than 40 (32, 48) min in the control group (P < 0.05). The volume of erythrocyte infusion in the ERAS group was 10 (7, 13) U, significantly less than 18 (10, 28) U in the control group (P < 0.05). The length of postoperative ICU stay and total length of hospital stay in the ERAS group were 135 (84, 212) h and 24 (18, 33) d, significantly shorter than 154 (103, 253) h and 34 (20, 50) d in the control group (both P < 0.05). Total ventilator removal time at postoperative 28 d was 26 (25, 27) d, significantly longer than 26 (23, 27) d in the control group (P < 0.05). The postoperative re-intubation rate in the ERAS group was 11.0%, significantly lower than 20.8% in the control group (P < 0.05). The 90 d, 180 d and 1-year survival rates in the ERAS group were 92.8%, which were significantly higher than 81.1%, 78.1% and 75.7% in the control group (all P < 0.05). ERAS and operation time were the independent influencing factors of survival rate of liver transplant recipients (both P < 0.05). Conclusions ERAS after liver transplantation can improve the survival rate of recipient, shorten the length of hospital stay, reduce the re-intubation rate and accelerate the rehabilitation after liver transplantation. -
表 1 肝移植受者生存率影响因素的单因素和多因素分析
Table 1. Univariate and multivariate analysis of influencing factors for survival rate of recipients after liver transplantation
影响因素 单因素分析 多因素分析 HR ①(95%CI ②) P值 HR(95%CI) P值 肾衰竭 否 1 1 是 1.58 (0.97~2.57) 0.067 7 1.86 (0.98~3.50) 0.055 7 手术时间 1.23 (1.08~1.40) 0.001 9 1.26 (1.10~1.45) 0.001 2 分组 对照组 1 1 ERAS组 0.30 (0.15~0.58) 0.000 4 0.25 (0.12~0.51) 0.000 1 MELD评分 1.01 (0.99~1.03) 0.364 9 1.01 (0.98~1.04) 0.381 0 合并肿瘤 0 1 1 1 1.06 (0.65~1.73) 0.807 9 1.33 (0.71~2.49) 0.381 3 无肝期 1.00 (0.98~1.02) 0.750 6 1.00 (0.97~1.02) 0.701 7 ACLF 3级 0 1 1 1 0.95 (0.58~1.56) 0.836 2 0.77 (0.33~1.79) 0.538 5 脑衰竭 否 1 1 是 1.01 (0.63~1.63) 0.952 2 1.13 (0.53~2.41) 0.753 5 既往腹部手术病史 0 1 1 1 1.06 (0.63~1.78) 0.836 3 0.85 (0.48~1.49) 0.564 7 注:①HR为风险比。
②CI为可信区间。 -
[1] 杨磊, 代世韬, 姚尚龙.肝移植麻醉精细化管理——科学与艺术的体现[J].器官移植, 2018, 9(6):414-416. DOI: 10.3969/j.issn.1674-7445.2018.06.003.YANG L, DAI ST, YAO SL. Precision management of liver transplantation anesthesia——the reflect of science and art [J]. Organ Transplant, 2018, 9(6):414-416. DOI: 10.3969/j.issn.1674-7445.2018.06.003. [2] BRUSTIA R, MONSEL A, CONTI F, et al. Enhanced recovery in liver transplantation: a feasibility study[J]. World J Surg, 2019, 43(1):230-241. DOI: 10.1007/s00268-018-4747-y. [3] LI M, ZHANG W, JIANG L, et al. Fast track for open hepatectomy: a systemic review and Meta-analysis[J]. Int J Surg, 2016, 36(Pt A):81-89. DOI: 10.1016/j.ijsu.2016.10.019. [4] MEDBERY RL, FERNANDEZ FG, KHULLAR OV. ERAS and patient reported outcomes in thoracic surgery: a review of current data[J]. J Thorac Dis, 2019, 11(Suppl 7): S976-S986. DOI: 10.21037/jtd.2019.04.08. [5] CAO Y, GU HY, HUANG ZD, et al. Impact of enhanced recovery after surgery on postoperative recovery for pancreaticoduodenectomy: pooled analysis of observational study[J]. Front Oncol, 2019, 9:687. DOI: 10.3389/fonc.2019.00687. [6] GRECO M, CAPRETTI G, BERETTA L, et al. Enhanced recovery program in colorectal surgery: a Meta-analysis of randomized controlled trials[J]. World J Surg, 2014, 38(6):1531-1541. DOI: 10.1007/s00268-013-2416-8. [7] LJUNGQVIST O, SCOTT M, FEARON KC. Enhanced recovery after surgery: a review[J]. JAMA Surg, 2017, 152(3):292-298. DOI: 10.1001/jamasurg.2016.4952. [8] MELLOUL E, HÜBNER M, SCOTT M, et al. Guidelines for perioperative care for liver surgery: enhanced recovery after surgery (ERAS) society recommendations[J]. World J Surg, 2016, 40(10):2425-2440. DOI: 10.1007/s00268-016-3700-1. [9] NEWMAN KL, JOHNSON KM, CORNIA PB, et al. Perioperative evaluation and management of patients with cirrhosis: risk assessment, surgical outcomes, and future directions[J]. Clin Gastroenterol Hepatol, 2019, DOI: 10.1016/j.cgh.2019.07.051[Epubahead of print]. [10] NI X, JIA D, GUO Y, et al. The efficacy and safety of enhanced recovery after surgery (ERAS) program in laparoscopic digestive system surgery: a Meta-analysis of randomized controlled trials[J]. Int J Surg, 2019, 69:108-115. DOI: 10.1016/j.ijsu.2019.07.034. [11] PUPPO MORENO AM, ABELLA ALVAREZ A, MORALES CONDE S, et al. The intensive care unit in the postoperative period of major abdominal surgery[J]. Med Intensiva, 2019, 43(9):569-577. DOI: 10.1016/j.medin. 2019.05.007. [12] DIETZ N, SHARMA M, ADAMS S, et al. Enhanced recovery after surgery (ERAS) for spine surgery: a systematic review[J]. World Neurosurg, 2019, 130:415-426. DOI: 10.1016/j.wneu.2019.06.181. [13] 乔华, 李钰, 李琳.肝移植术后患者疲劳状况与依从性和生命质量的相关性研究[J].中国实用护理杂志, 2017, 33(33):2585-2589.DOI:10.3760/cma.j.issn.1672- 7088.2017.33.006.QIAO H, LI Y, LI L. The relationship between status of fatigue and compliance, quality of life in patients after liver transplantation[J]. Chin J Pract Nurs, 2017, 33(33):2585-2589. DOI: 10.3760/cma.j.issn.1672-7088.2017.33.006. [14] ABY ES, SAAB S. Frailty, sarcopenia, and malnutrition in cirrhotic patients[J]. Clin Liver Dis, 2019, 23(4):589-605. DOI: 10.1016/j.cld.2019.06.001. [15] CZIGANY Z, KRAMP W, BEDNARSCH J, et al. Myosteatosis to predict inferior perioperative outcome in patients undergoing orthotopic liver transplantation[J]. Am J Transplant, 2019, DOI: 10.1111/ajt.15577[Epubahead of print]. [16] WILLIAMS FR, BERZIGOTTI A, LORD JM, et al. Review article: impact of exercise on physical frailty in patients with chronic liver disease[J]. Aliment Pharmacol Ther, 2019, 50(9):988-1000. DOI: 10.1111/apt.15491. [17] DONG V, SUN K, GOTTFRIED M, et al. Significant lung injury and its prognostic significance in acute liver failure: a cohort analysis[J]. Liver Int, 2019, DOI: 10.1111/liv.14268[Epubahead of print]. [18] KING AB, KENSINGER CD, SHI Y, et al. Intensive care unit enhanced recovery pathway for patients undergoing orthotopic liver transplants recipients: a prospective, observational study[J]. Anesth Analg, 2018, 126(5):1495-1503. DOI: 10.1213/ANE.0000000000002851. [19] HOPP AE, DIRKS M, PETRUSCH C, et al. Hepatic encephalopathy is reversible in the long term after liver transplantation[J]. Liver Transpl, 2019, 25(11):1661-1672. DOI: 10.1002/lt.25626. [20] STRAVITZ RT, LEE WM. Acute liver failure[J]. Lancet, 2019, 394(10201):869-881.DOI: 10.1016/S0140-6736(19) 31894-X. [21] KWON HM, MOON YJ, JUNG KW, et al. Appraisal of cardiac ejection fraction with liver disease severity: implication in post-liver transplantation mortality[J]. Hepatology, 2019, DOI: 10.1002/hep.30913[Epubahead of print]. [22] CARRIER FM, CHASSé M, WANG HT, et al. Restrictive fluid management strategies and outcomes in liver transplantation: a systematic review[J]. Can J Anaesth, 2020, 67(1):109-127. DOI: 10.1007/s12630-019-01480-y. [23] 中国医师协会器官移植分会移植免疫学组, 中华医学会外科学分会手术学组, 广东省医师协会器官移植医师分会.加速康复外科优化重型肝炎肝移植围手术期管理临床实践的专家共识[J].临床肝胆病杂志, 2017, 33(9):1646-1654.DOI: 10.3969/j.issn.1001-5256.2017.09.05.Transplantation Immunology Group of Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Surgical Group of Branch of Surgery of Chinese Medical Association, Branch of Organ Transplant Physician of Guangdong Medical Doctor Association. Expert consensus on the optimization of perioperative management of liver transplantation for severe hepatitis by enhanced recovery after surgery[J]. J Clin Hepatol, 2017, 33(9):1646-1654. DOI: 10.3969/j.issn.1001-5256.2017.09.05. [24] KASRAIAN L, NIKEGHBALIAN S, KARIMI MH. Blood product transfusion in liver transplantation and its impact on short-term survival[J]. Int J Organ Transplant Med, 2018, 9(3):105-111. http://cn.bing.com/academic/profile?id=61188974784471d79ad92e3701d910ce&encoded=0&v=paper_preview&mkt=zh-cn